TNF and metabolic dysfunction-associated steatotic liver disease: These findings are supported by several studies demonstrating that anti-TNF antibody treatment or metformin, which inhibits hepatic TNF-α expression, alleviates hepatic steatosis [33–35] and that multiple dysregulation-inducing processes may simultaneously contribute to the development NAFLD and low-grade systemic inflammation.